Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Unfortunately, the antibody (ID:156096) is no longer available.
Below is a list of antibodies to the same protein target. You may also try your search again using the search box at the top of the page.
Please contact us if you have any questions.
CD274 / B7-H1 / PD-L1
CD274, also known as B7-H1 and PD-L1, a cell surface glycoprotein, is a member of the B7 family of co-stimulatory molecules. CD274 is expressed constitutively on macrophages and dendritic cells, and is induced on activated T-cells, B-cells, endothelial cells and epithelial cells in response to interferons. CD274 has dual functions: inhibition of activated effector T cells and co-stimulation of naïve T cells. It inhibits proliferation of activated T cells via ligation to the co-inhibitory molecule CD279 (programmed death-1; PD-1) leading to the secretion of the regulatory cytokine interleukin-10. Expression of CD274 in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma.
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 19:1225-31. (WB; Human)[Full Text Article]
Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K, Takigawa N. American journal of cancer research. 2015 5:1553-7. (Flo; Human)
Related Antibodies: LS-C188354.
Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Karakhanova S, Link J, Heinrich M, Shevchenko I, Yang Y, Hassenpflug M, Bunge H, von Ahn K, Brecht R, Mathes A, Maier C, Umansky V, Werner J, Bazhin AV. Oncoimmunology. 2015 4:e998519. (Flo; Mouse)[Full Text Article]
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Beldi-Ferchiou A, Lambert M, Dogniaux S, Vély F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbé C, Sène D, Hivroz C, Caillat-Zucman S. Oncotarget. 2016 7:72961-72977. (WB; Human)[Full Text Article]
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1a and STAT3. Koh J, Jang JY, Keam B, Kim S, Kim MY, Go H, Kim TM, Kim DW, Kim CW, Jeon YK, Chung DH. Oncoimmunology. 2016 5:e1108514. (Flo; Human)[Full Text Article]
Related Antibodies: LS-C188353.
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 21:4014-21. (WB; Human)[Full Text Article]
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 25:1935-40. (WB; Human)[Full Text Article]
Neuronal programmed cell death-1 ligand expression regulates retinal ganglion cell number in neonatal and adult mice. Sham CW, Chan AM, Kwong JM, Caprioli J, Nusinowitz S, Chen B, Lee JG, Gandhi NM, Francisco LM, Sharpe AH, Chen L, Braun J, Gordon LK. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2012 32:227-37. (WB; Human)[Full Text Article]